Emapalumab Prevention of CAR-T Cell Associated Toxicities

This study is testing whether a drug called emapalumab can help prevent dangerous side effects — specifically cytokine release syndrome (CRS) and neurological toxicities — that can occur after CAR-T cell therapy. CAR-T is a powerful immune cell treatment for large B-cell lymphoma (a blood cancer), and these side effects can be life-threatening. Emapalumab blocks a molecule called interferon-gamma that drives these reactions. **You may be eligible if...** - You are an adult with large B-cell lymphoma (including DLBCL, primary mediastinal large B-cell lymphoma, or high-grade B-cell lymphoma) that: - Did not respond to or came back within 12 months of initial chemoimmunotherapy, OR - Relapsed or is refractory after two or more prior treatment lines - You have at least one measurable lymphoma lesion - At least 2 weeks have passed since your last systemic therapy **You may NOT be eligible if...** - You have active uncontrolled infections - Your heart, liver, kidneys, or lungs are not functioning well enough - You are pregnant or breastfeeding - You have had a prior CAR-T cell therapy - You have active brain involvement from lymphoma Talk to your doctor to see if this trial is right for you.